2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179620
    AChE-IN-99
    AChE-IN-99 (Compound 5a) is an AChE inhibitor. AChE-IN-99 can be used for the research of Alzheimer's disease.
    AChE-IN-99
  • HY-179621
    EQ-04
    EQ-04 is a highly selective positive allosteric modulator (PAM) of α7 nAChR. EQ-04 has no direct inhibitory activity on AChE and BChE. EQ-04 inhibits Aβ aggregation. EQ-04 has safe cytotoxicity and potent neuroprotective activity. EQ-04 can be used for the study of Alzheimer's disease.
    EQ-04
  • HY-179624
    cGAS-IN-7
    cGAS-IN-7 is a cyclic GMP-AMP synthase (cGAS) inhibitor with an IC50 of 0.66 μM for human cGAS. cGAS-IN-7 modestly decreases cGAMP levels in THP1 cells. cGAS-IN-7 can be used for the research of Alzheimer's disease.
    cGAS-IN-7
  • HY-179646
    CIAC101 3122563-80-5 98%
    CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease.
    CIAC101
  • HY-179657
    PROTAC MLT Degrader 1 98%
    PROTAC MLT Degrader 1 (M-PRORAC) is an asymmetric dual-functional degrader based on MLT PROTAC. PROTAC MLT Degrader 1 significantly reduces the protein level of p300 in the cell. PROTAC MLT Degrader 1 can be used in Alzheimer's disease research (pink: MLT ligand (HY-B0075); blue: CRBN ligand (HY-41547); black: linker (HY-140208)).
    PROTAC MLT Degrader 1
  • HY-179684
    PCC0105005 2921670-99-5
    PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine.
    PCC0105005
  • HY-179705
    MOR agonist-5 3085132-31-3
    MOR agonist-5 is a selective and potent mu-opioid receptor (MOR) agonist with an EC50 of 0.25 nM. MOR agonist-5 shows an EC50 of 10 nM for DOR and >10000 nM for KOR and NOR. MOR agonist-5 exerts significant antinociceptive activity. MOR agonist-5 can be used for the research of pain.
    MOR agonist-5
  • HY-179711
    AChE/BChE-IN-32
    AChE/BChE-IN-32 (Compound 4a) is an AChE and BChE inhibitor, with Ki values of 2.48 and 0.696 μM respectively. AChE/BChE-IN-32 inhibits Aβ aggregation and exhibits a strong ABTS•+ scavenging ability (TEAC = 2.40). AChE/BChE-IN-32 shows significant neuroprotective activity in glutamate and hydrogen peroxide-induced oxidative stress models. AChE/BChE-IN-32 can be used for the study of Alzheimer's disease.
    AChE/BChE-IN-32
  • HY-179713
    D2R/D3R/5-HT1AR agonist 1 3028684-07-0
    D2R/D3R/5-HT1AR agonist 1 (compound 22b) is an orally active triple-target D2R/D3R/5-HT1AR agonist with EC50 values of 1.29, 1.05 and 153.5 nM. D2R/D3R/5-HT1AR agonist 1 can improve the behavioral disorders induced by MPTP (HY-W114750) and exerts anti-depression effect. D2R/D3R/5-HT1AR agonist 1 can be used for the research of Parkinson's disease and depression.
    D2R/D3R/5-HT1AR agonist 1
  • HY-179714
    DAM-001 1090396-31-8
    DAM-001 (Z236004662) is a potent, non-competitive allosteric inhibitor for human dopamine transporter (hDAT) with an IC50 of 24.70 μM and 1.026 μM in the absence and presence of orthosteric inhibitor Nomifensine (HY-B1110).
    DAM-001
  • HY-179723
    GSK3β-IN-4 3083425-61-7 98%
    GSK3β-IN-4 is a selective, potent, orally active and brain-penetrant ATP-competitive GSK3β inhibitor with an IC50 of 0.37 nM. GSK3β-IN-4 shows an IC50 of 2.75 nM and SI of 7.4 for GSK3α. GSK3β-IN-4 reduces tau phosphorylation at Ser396 by inhibiting GSK3β and imoroves cognitive deficits in Alzheimer's disease models. GSK3β-IN-4 can be used for the research of Alzheimer's disease.
    GSK3β-IN-4
  • HY-179724
    PZ-1657
    PZ-1657 (Compound 57) is an orally active, blood-brain barrier permeable, highly selective, and metabolically stable 5-HT7 receptor inverse agonist with a Ki value of 5 nM. PZ-1657 inhibits constitutive cyclic adenosine monophosphate (cAMP) production mediated by the Gs signaling pathway (EC50 value of 2.93 nM). PZ-1657 inhibits CYP3A4 P450 (IC50 = 12.2 μM) and hERG channels. PZ-1657 reduces 5-HT7 receptor-mediated MMP-9 activity. PZ-1657 reverses Phencyclidine-induced cognitive impairment. PZ-1657 possesses antidepressant properties.
    PZ-1657
  • HY-179725
    PZ-1129 1919029-61-0 98%
    PZ-1129 is a selective 5-HT7 receptor ligand with a Ki of 7 nM. PZ-1129 shows Ki values of 159 and 24 nM for 5-HT1A receptor and D2 receptor. PZ-1129 can inhibit the constitutive cAMP production mediated by the Gs signaling pathway (EC50 = 13.7 nM). PZ-1129 can be used for the research of emotional disorders, such as depression and bipolar disorder.
    PZ-1129
  • HY-179726
    BChE-IN-47
    BChE-IN-47 (Compound 13) is a selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 0.045 μM. BChE-IN-47 enhances the level of acetylcholine in the brain by selectively inhibiting BChE, thereby improving cognitive function. BChE-IN-47 can be used for the research of Alzheimer’s disease.
    BChE-IN-47
  • HY-180056
    CAII-IN-12
    CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II Ki = 47.8 nM, hCA VII Ki = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research.
    CAII-IN-12
  • HY-180087
    GABA-AT-IN-2 898468-56-9
    GABA-AT-IN-2 (compound 11g) is a GABA aminotransferase (GABA-AT) inhibitor with an IC50 of 19.8 μM. GABA-AT-IN-2 demonstrates notable antianxiety effects in mice. GABA-AT-IN-2 can be used for anxiety-related neurotic disorders research.
    GABA-AT-IN-2
  • HY-180109
    Benzo-17R-RvD2 98%
    Benzo-17R-RvD2 (Benzo-17R-Resolvin D2) is a benzo-containing analog of RvD2 (HY-121636). Benzo-17R-RvD2 enhances human macrophage efferocytosis, limits neutrophil infiltration, reduces TNF-α, and increases IL-1 receptor antagonist in peritonitis. Benzo-17R-RvD2 promotes E. coli killing by human leukocytes and reduces neutrophil swarm area without compromising anti-Candida activity. Benzo-17R-RvD2 activates the human-RvD2 receptor with an EC50 ∼1.5 nM. Benzo-17R-RvD2 can be used in research on inflammation-associated diseases such as cardiovascular disease, cancer, neuroinflammation, pain, and muscle regeneration.
    Benzo-17R-RvD2
  • HY-180111
    PLK4-IN-7
    PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma.
    PLK4-IN-7
  • HY-180113
    AChE-IN-100
    AChE-IN-100 (Compound 5n) is an AChE inhibitor with an IC50 of 2.38 nM. AChE-IN-100 shows superior ROS-scavenging capabilities. AChE-IN-100 has antioxidant capacity. AChE-IN-100 shows a significant neuroprotective effect against hydrogen peroxide-induced damage. AChE-IN-100 can be used in the research of Alzheimer’s diseases.
    AChE-IN-100
  • HY-180114
    NSS-18
    NSS-18 is a potent and reversible inhibitor of AChE and MAO-B, with IC50 values of 1.53 and 1.51 μM respectively. NSS-18 can inhibit the self-aggregation of Aβ. NSS-18 inhibits the intracellular generation of ROS induced by Aβ. NSS-18 shows a moderate neuroprotective effect against 6-OHDA (HY-B1081)-induced neurotoxicity. NSS-18 can form chelates with metal ions such as Cu²⁺, Fe³⁺, and Zn²⁺, with the strongest chelation being with Cu²⁺. NSS-18 can be used for the study of Alzheimer's disease.
    NSS-18
Cat. No. Product Name / Synonyms Application Reactivity